Crossmark

Substitution of ifosfamide for cyclophosphamide in the TI-CE regimen: pharmacology and dose justification in a patient with refractory metastatic germ-cell tumor post-nephrectomy—A case report

Crossref DOI link: https://doi.org/10.1007/s00280-025-04818-0

Published Online: 2025-10-22

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hulskotte, Lotte M. G.

de Jong, Loek A. W.

Huitema, Alwin D. R.

Sijm, Joost

Desar, Ingrid

Smits, Minke

van Erp, Nielka P.
License Information

Text and Data Mining valid from 2025-10-22

Version of Record valid from 2025-10-22
More Information

Article History

Received: 20 June 2025

Accepted: 16 September 2025

First Online: 22 October 2025

Declarations

:

: The authors declare no competing interests.

: Written informed consent was obtained from the patient for publication of the details of his medical case. The participant has consented to the submission of the case report to the journal.

Document is current

Any future updates will be listed below